Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
- Dr. Shaughnessy Discusses Stem Cell Mobilization in Lymphomas on February 24, 2019 at 1:26 pm
Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses stem cell mobilization in patients with lymphomas. There are a variety of ch... […]
- Family hosts stem cell donor drive at Surrey gurdwara for relative’s second time battling cancer on February 23, 2019 at 6:07 pm
The reason for the stem cell drive, according to a news release for the event, is to get a perfect match for him by the end of February “for the best chance of his transplant being successful.” Along ... […]
- Dr. Dandoy on TMA Risk After Pediatric Allogenic Stem Cell Transplant on February 23, 2019 at 9:33 am
Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombo... […]
- Stem Cells May Be Universally Transplanted on February 22, 2019 at 4:39 pm
... crisis due to the global shortage of donated organs but also because of the high risk of organ transplant rejections. A new type of universal stem cell may help to solve some of these issues, as p... […]
- Engineered 'suicide genes' prevent tumors in stem cell-derived beta cells on February 19, 2019 at 10:51 am
However, transplantation of these immature cells into patients poses substantial risks, namely the development of tumors (teratomas) and the growth of these stem cells into unwanted cell types. Plurip... […]
- Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors on February 19, 2019 at 10:17 am
High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHSCT) is a well-established treatment for pediatric central nervous system (CNS) tumors. Given the risks of toxicity ... […]
- CRISPR Gene Editing Makes Stem Cells ‘Invisible’ to Immune System on February 19, 2019 at 6:06 am
Unfortunately, these immunosuppressants leave patients more susceptible to infection and cancer,” explained Professor of Surgery Sonja Schrepfer, MD, PhD, the study’s senior author and director of the ... […]
- A stem cell transplant with a twist. ‘They are connected in so many ways’ on February 15, 2019 at 4:29 am
She was a Florida college student with cancer. He lived in Kentucky. Their blood and bone marrow matched, and he helped save her life. Soon he’ll preside at her wedding. It's been years since they met ... […]
- Autologous stem cell transplant may aid some with nodal PTCL on February 14, 2019 at 6:12 am
(HealthDay)—Autologous stem cell transplantation (ASCT) may be beneficial for some patients with nodal peripheral T-cell lymphoma (PTCL) in the first complete remission (CR1), according to a ... […]
- Faster Cell Recovery After Cord Blood Transplant on February 13, 2019 at 2:34 pm
Ex vivo expansion of umbilical cord blood (UCB) grafts by means of a stem cell-associated protein led to significantly quicker hematopoietic recovery after transplantation with less graft versus host ... […]
via Google News and Bing News